Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Sloma

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Experimental Hematology|June 13, 2017
Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemiaIvan Sloma, Maria Teresa Mitjavila-Garcia, Olivier Feraud, et al.
Journal of the National Cancer Institute|March 1, 2013
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complexMin Chen, Paolo Gallipoli, Donna DeGeer, et al.
Leukemia|June 18, 2025
A molecular signature predicts hematologic evolution in polycythemia vera patientsOlivier Mansier, Eric Lippert, Lina Benajiba, et al.
Blood Advances|March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM studyDamien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
Hemasphere|January 22, 2025
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLLSarka Pavlova, Jitka Malcikova, Lenka Radova, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Experimental Hematology|June 13, 2017
Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemiaIvan Sloma, Maria Teresa Mitjavila-Garcia, Olivier Feraud, et al.
Journal of the National Cancer Institute|March 1, 2013
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complexMin Chen, Paolo Gallipoli, Donna DeGeer, et al.
Leukemia|June 18, 2025
A molecular signature predicts hematologic evolution in polycythemia vera patientsOlivier Mansier, Eric Lippert, Lina Benajiba, et al.
Blood Advances|March 5, 2021
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM studyDamien Luque Paz, Jérémie Riou, Emmanuelle Verger, et al.
Hemasphere|January 22, 2025
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLLSarka Pavlova, Jitka Malcikova, Lenka Radova, et al.
Pageof 3